NPCE
Neuropace Inc
13.20$
-4.4%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | -1,266.0% | – | – | |
| – | +2.8% | +3.4% | +5.0% | +1.6% | +0.0% | +2.4% | +3.2% | +2.1% | +7.2% | -1.7% | +3.3% | – | |
| – | -2.6% | +7.8% | +0.3% | +1.7% | +0.5% | +0.9% | +22.9% | -18.6% | -0.8% | -12.6% | +1.1% | – | |
| – | -167.8% | – | – | – | -648.0% | – | – | -179.8% | – | – | – | – | |
| – | +255.6% | +225.0% | -39.4% | +58.7% | -61.0% | -5.1% | +354.1% | -82.1% | +223.3% | +20.6% | +6.8% | – | |
| – | -17.3% | -30.9% | +35.1% | -56.8% | +40.1% | -101.9% | +354.1% | -82.1% | +223.3% | +20.6% | +6.8% | – | |
| – | +5.7% | +1,654.1% | -88.9% | -5.6% | +35.3% | +53,754.3% | -100.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | |
| – | – | -99.1% | +606.9% | +469.4% | -70.7% | +2,389.2% | -109.0% | -87.7% | – | -126.1% | – | – | |
| – | +348.0% | -160.7% | – | – | -177.2% | – | -130.6% | – | – | -762.2% | – | – | |
| – | – | – | – | – | – | – | – | – | – | -1,571.1% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.